一分钟看懂
这是一项关于小细胞肺癌的II 期研究，登记的药物或干预包括Adebrelimab；Apatinib Mesylate；Etoposide；Carboplatin，当前状态为招募中。登记地点显示中国杭州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Adebrelimab；Apatinib Mesylate；Etoposide；Carboplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Zhejiang Cancer Hospital · 杭州
公开的入选条件
- * Age between 18 and 75 years old;
- * Histologically or cytologically confirmed limited-stage small cell lung cancer (T1-3N0-1M0).
- * All lesions of the patient (including the primary lesion, lymph nodes/lesions assessed as metastatic) must be jointly evaluated and confirmed as resectable by a surgeon, a radiation oncologist, and a radiologist;
- * The subject must have measurable target lesions (according to RECIST 1.1 criteria);
- * ECOG performance status score of 0-1;
- * No history of other malignancies;
- * No previous treatment for small cell lung cancer-related surgery, radiotherapy, chemotherapy, immunotherapy, or other anti-tumor treatments;
- * The patient must have adequate cardiopulmonary function: the patient's FEV1 and DLCO are both ≥50% of the predicted value, echocardiography shows LVEF ≥55%, and no clear signs of heart failure, severe coronary artery stenosis, etc., are seen on various tests
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06483282；登记信息更新于 2026-09-11。